CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Finch Therapeutics Group Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Finch Therapeutics Group Inc
75 State Street, Suite 100
Phone: (475) 238-6837p:475 238-6837 BOSTON, MA  02109  United States Fax: (302) 636-5454f:302 636-5454
This company's Plan of Liquidation went into effect on 9/30/2026
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Its portfolio of microbiome assets is designed with insights from human microbiota transplantation studies. These studies involve the transfer of microbiota from healthy individuals to individuals with disease, an area of intense research with hundreds of third-party clinical studies spanning dozens of different conditions. Its assets include CP101, an investigational, orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection, or CDI, with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has developed a significant biorepository of strains and samples.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYesYes--

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board ChristianLange 44 4/1/2024 9/1/2017
President, Chief Executive Officer, Secretary Matthew P.Blischak 61 5/16/2023 5/16/2023
Chief Financial Officer Lance E.Thibault 57 5/16/2023 5/16/2023
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Finch Research and Development, LLC
Finch Therapeutics Holdings, LLC
Finch Therapeutics, Inc.

General Information
Outstanding Shares: 1,605,763 (As of 8/9/2024)
Shareholders: 66
Stock Exchange: OTC
Federal Tax Id: 823433558
Fax Number: (302) 636-5454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026